Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

298 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma.
Bergerot C, Young Rha S, Pal S, Koralewski P, Stroyakovskiy D, Alekseev B, Parnis F, Castellano D, Lyun Lee J, Sunela K, Ciuleanu T, Heng D, Glen H, Wang J, Bennett L, Pan J, O'Hara K, Puente J. Bergerot C, et al. Oncologist. 2023 Jan 18;28(1):59-71. doi: 10.1093/oncolo/oyac142. Oncologist. 2023. PMID: 35881028 Free PMC article. Clinical Trial.
Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial.
Pal SK, Puente J, Heng DYC, Glen H, Koralewski P, Stroyakovskiy D, Alekseev B, Parnis F, Castellano D, Ciuleanu T, Lee JL, Sunela K, O'Hara K, Binder TA, Peng L, Smith AD, Rha SY. Pal SK, et al. Eur Urol. 2022 Sep;82(3):283-292. doi: 10.1016/j.eururo.2021.12.024. Epub 2022 Feb 21. Eur Urol. 2022. PMID: 35210132 Free article. Clinical Trial.
Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011.
O'Donnell PH, Loriot Y, Csoszi T, Matsubara N, Shin SJ, Park SH, Atduev V, Gumus M, Karaca SB, Grivas P, de Wit R, Castellano DE, Powles T, Vuky J, Zhao Y, O'Hara K, Okpara CE, Franco S, Homet Moreno B, Żołnierek J, Siefker-Radtke AO. O'Donnell PH, et al. Among authors: o hara k. Cancer. 2025 Jan 1;131(1):e35601. doi: 10.1002/cncr.35601. Epub 2024 Oct 28. Cancer. 2025. PMID: 39465550 Free PMC article.
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.
Matsubara N, de Wit R, Balar AV, Siefker-Radtke AO, Zolnierek J, Csoszi T, Shin SJ, Park SH, Atduev V, Gumus M, Su YL, Karaca SB, Cutuli HJ, Sendur MAN, Shen L, O'Hara K, Okpara CE, Franco S, Moreno BH, Grivas P, Loriot Y. Matsubara N, et al. Eur Urol. 2024 Mar;85(3):229-238. doi: 10.1016/j.eururo.2023.08.012. Epub 2023 Sep 29. Eur Urol. 2024. PMID: 37778952 Free article. Clinical Trial.
298 results